HIV

News

Janssen HIV Symtuza darunavir cobicistat emtricitabine tenofovir alafenamide

FDA approves Janssen's HIV combination Symtuza

Janssen has won US approval for its once-daily HIV pill Symtuza (D/C/F/TAF), which it hopes will improve patient adherence and resistance to treatment.

News

Study indicates potential breakthrough HIV drug

French biotech Abivax might be on the verge of HIV cure and prevention discovery, after achieving a significant reduction of viral load patients during the first 28 days of treatment.

News

GSK's blockbuster HIV drug linked with birth defects

Regulators issue warning after preliminary study findings

News

Image concept with the result of the HIV test.

ViiV's HIV drug could be used for TB co-infection patients

Interim results suggest new treatment option for patients with TB and HIV

News

Gilead takes 'HIV eradication' combo into clinic

New approach tackles reserve of HIV within the body

News

GSK's newly approved HIV treatment Juluca expected to domina...

The FDA has approved an HIV dual therapy developed by GSK’s specialist joint venture, ViiV Healthcare, a convenient combination that will compete with Gilead's nearly-approved three-drug re

FDA approves Janssen's HIV combination Symtuza

Study indicates potential breakthrough HIV drug

GSK's blockbuster HIV drug linked with birth defects

ViiV's HIV drug could be used for TB co-infection patients

Gilead takes 'HIV eradication' combo into clinic

GSK's newly approved HIV treatment Juluca expected to domina...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

HIV

Editor's Picks